Trial Profile
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Burosumab (Primary)
- Indications X-linked dominant hypophosphataemic rickets
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 30 May 2014 New trial record
- 12 May 2014 Data from the phase I/II adult repeat-dose studies completed by Ultragenyx's collaborative partner Kyowa Hakko Kirin Co., Ltd. are expected to be released at scientific conferences in 2014.